ZNF217 and breast carcinoma: Most importantly, our data suggest that clinical strategies counteracting ZNF217-mediated effects, either by targeting ZNF217 directly and/or by targeting its possible key-mediators like Aurora-A, would be a valuable approach for the management of breast cancer.